Foresite expands Alumis (ALMS) position to 14.1% in Schedule 13D/A

Rhea-AI Filing Summary

Foresite Capital entities and James B. Tananbaum have updated their disclosure of ownership in Alumis Inc. common stock in this Amendment No. 3 to Schedule 13D. The filing shows that Tananbaum is deemed to beneficially own 16,189,804 shares, or 14.1% of Alumis’s common stock, through a network of Foresite funds and affiliated LLCs.

The amendment reflects dilution from Alumis issuing additional shares and new purchases, including participation in the July 2024 IPO at $16.00 per share, multiple open-market purchases in 2025, and a follow-on offering on January 8, 2026 where Fund V and Opportunity Fund V bought shares at $17.00 per share. The reporting persons state they hold the position for investment purposes and may buy more, hold, sell, or distribute shares depending on market conditions and their assessment of Alumis’s business.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)

Alumis Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

022307102

(CUSIP Number)

Amelia Stoj
900 Larkspur Landing Circle, Suite 150,
Larkspur, CA, 94939
(203) 687-6536

Phyllis Solomon
101 Mission Street, 12th Floor,
San Francisco, CA, 94105
(415) 787-6009

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

01/08/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 022307102

1

Name of reporting person

Foresite Capital Fund VI LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 4,247,670.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 4,247,670.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

4,247,670.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.7 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Note to Row 7: 4,247,670 shares, except that Foresite Capital Management VI, LLC ("FCM VI"), the general partner of Foresite Capital Fund VI LP ("Fund VI"), may be deemed to have sole power to vote these shares, and James B. Tananbaum ("Tananbaum"), the managing member of FCM VI, may be deemed to have sole power to vote these shares. Note to row 8: See response to row 7. Note to Row 9: 4,247,670 shares, except that FCM VI, the general partner of Fund VI, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM VI, may be deemed to have sole power to dispose of these shares. Note to Row 10: See response to row 9. Note to Row 13: This percentage is calculated based upon 114,824,231 shares of common stock of Alumis, Inc. (the "Issuer") outstanding as of January 8, 2026, as set forth in the Issuer's Form 424B5 filed with the Securities Exchange Commission on January 8, 2026.

SCHEDULE 13D

CUSIP No. 022307102

1

Name of reporting person

Foresite Capital Management VI, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 4,247,670.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 4,247,670.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

4,247,670.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.7 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Note to Row 7: 4,247,670 shares, all of which are directly owned by Fund VI. FCM VI, the general partner of Fund VI, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM VI, may be deemed to have sole power to vote these shares. Note to row 8: See response to row 7. Note to Row 9: 4,247,670 shares, all of which are directly owned by Fund VI. FCM VI, the general partner of Fund VI, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM VI, may be deemed to have sole power to dispose of these shares. Note to Row 10: See response to row 9. Note to Row 13: This percentage is calculated based upon 114,824,231 shares of common stock of the Issuer outstanding as of January 8, 2026, as set forth in the Issuer's Form 424B5 filed with the Securities Exchange Commission on January 8, 2026.

SCHEDULE 13D

CUSIP No. 022307102

1

Name of reporting person

Foresite Capital Fund V, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 5,702,536.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 5,702,536.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

5,702,536.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.0 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Note to Row 7: 5,702,536 shares, except that Foresite Capital Management V, LLC ("FCM V"), the general partner of Foresite Capital Fund V, L.P. ("Fund V"), may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to vote these shares. Note to row 8: See response to row 7. Note to Row 9: 5,702,536 shares, except that FCM V, the general partner of Fund V, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to dispose of these shares. Note to Row 10: See response to row 9. Note to Row 13: This percentage is calculated based upon 114,824,231 shares of common stock of the Issuer outstanding as of January 8, 2026, as set forth in the Issuer's Form 424B5 filed with the Securities Exchange Commission on January 8, 2026.

SCHEDULE 13D

CUSIP No. 022307102

1

Name of reporting person

Labs Co-Invest V, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 194,459.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 194,459.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

194,459.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.2 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Note to Row 7: 194,459 shares, except that FCM V, the managing member of Labs Co-Invest V, LLC ("Labs Co-Invest"), may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to vote these shares. Note to row 8: See response to row 7. Note to Row 9: 194,459 shares, except that FCM V, the managing member of Labs Co-Invest, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to dispose of these shares. Note to Row 10: See response to row 9. Note to Row 13: This percentage is calculated based upon 114,824,231 shares of common stock of the Issuer outstanding as of January 8, 2026, as set forth in the Issuer's Form 424B5 filed with the Securities Exchange Commission on January 8, 2026.

SCHEDULE 13D

CUSIP No. 022307102

1

Name of reporting person

Foresite Capital Management V, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 5,896,995.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 5,896,995.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

5,896,995.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.1 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Note to Row 7: 5,896,995 shares, of which 5,702,536 shares are directly owned by Fund V and 194,459 shares are directly owned by Labs Co-Invest. FCM V, the general partner of Fund V and the managing member of Labs Co-Invest, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to vote these shares. Note to row 8: See response to row 7. Note to Row 9: 5,896,995 shares, of which 5,702,536 shares are directly owned by Fund V and 194,459 shares are directly owned by Labs Co-Invest. FCM V, the general partner of Fund V and the managing member of Labs Co-Invest, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to dispose of these shares. Note to Row 10: See response to row 9. Note to Row 13: This percentage is calculated based upon 114,824,231 shares of common stock of the Issuer outstanding as of January 8, 2026, as set forth in the Issuer's Form 424B5 filed with the Securities Exchange Commission on January 8, 2026.

SCHEDULE 13D

CUSIP No. 022307102

1

Name of reporting person

Foresite Capital Opportunity Fund V, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 2,908,332.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 2,908,332.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

2,908,332.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.5 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Note to Row 7: 2,908,332 shares, except that Foresite Capital Opportunity Management V, LLC ("FCOM V"), the general partner of Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"), may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCOM V, may be deemed to have sole power to vote these shares. Note to row 8: See response to row 7. Note to Row 9: 2,908,332 shares, except that FCOM V, the general partner of Opportunity Fund V, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCOM V, may be deemed to have sole power to dispose of these shares. Note to Row 10: See response to row 9. Note to Row 13: This percentage is calculated based upon 114,824,231 shares of common stock of the Issuer outstanding as of January 8, 2026, as set forth in the Issuer's Form 424B5 filed with the Securities Exchange Commission on January 8, 2026.

SCHEDULE 13D

CUSIP No. 022307102

1

Name of reporting person

Foresite Capital Opportunity Management V, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 2,908,332.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 2,908,332.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

2,908,332.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.5 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Note to Row 7: 2,908,332 shares, all of which are directly owned by Opportunity Fund V. FCOM V, the general partner of Opportunity Fund V, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCOM V, may be deemed to have sole power to vote these shares. Note to row 8: See response to row 7. Note to Row 9: 2,908,332 shares, all of which are directly owned by Opportunity Fund V. FCOM V, the general partner of Opportunity Fund V, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCOM V, may be deemed to have sole power to dispose of these shares. Note to Row 10: See response to row 9. Note to Row 13: This percentage is calculated based upon 114,824,231 shares of common stock of the Issuer outstanding as of January 8, 2026, as set forth in the Issuer's Form 424B5 filed with the Securities Exchange Commission on January 8, 2026.

SCHEDULE 13D

CUSIP No. 022307102

1

Name of reporting person

Foresite Labs Fund I, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,960,337.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 1,960,337.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

1,960,337.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.7 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Note to Row 7: 1,960,337 shares, except that Foresite Labs Management I, LLC ("FLM I"), the general partner of Foresite Labs Fund I, L.P. ("Labs Fund I"), may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FLM I, may be deemed to have sole power to vote these shares. Note to row 8: See response to row 7. Note to Row 9: 1,960,337 shares, except that FLM I, the general partner of Labs Fund I, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FLM I, may be deemed to have sole power to dispose of these shares. Note to Row 10: See response to row 9. Note to Row 13: This percentage is calculated based upon 114,824,231 shares of common stock of the Issuer outstanding as of January 8, 2026, as set forth in the Issuer's Form 424B5 filed with the Securities Exchange Commission on January 8, 2026.

SCHEDULE 13D

CUSIP No. 022307102

1

Name of reporting person

Foresite Labs Management I, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,960,337.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 1,960,337.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

1,960,337.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.7 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Note to Row 7: 1,960,337 shares, all of which are directly owned by Labs Fund I. FLM I, the general partner of Labs Fund I, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FLM I, may be deemed to have sole power to vote these shares. Note to row 8: See response to row 7. Note to Row 9: 1,960,337 shares, all of which are directly owned by Labs Fund I. FLM I, the general partner of Labs Fund I, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FLM I, may be deemed to have sole power to dispose of these shares. Note to Row 10: See response to row 9. Note to Row 13: This percentage is calculated based upon 114,824,231 shares of common stock of the Issuer outstanding as of January 8, 2026, as set forth in the Issuer's Form 424B5 filed with the Securities Exchange Commission on January 8, 2026.

SCHEDULE 13D

CUSIP No. 022307102

1

Name of reporting person

Foresite Labs Affiliates 2021, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,176,470.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 1,176,470.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

1,176,470.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.0 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Note to Row 7: 1,176,470 shares, except that Foresite Labs, LLC ("Labs"), the managing member of Foresite Labs Affiliates 2021, LLC ("Labs Affiliates"), may be deemed to have sole power to vote these shares, and Tananbaum, a manager of Labs, may be deemed to have sole power to vote these shares. Note to row 8: See response to row 7. Note to Row 9: 1,176,470 shares, except that Labs, the managing member of Labs Affiliates, may be deemed to have sole power to dispose of these shares, and Tananbaum, a manager of Labs, may be deemed to have sole power to dispose of these shares. Note to Row 10: See response to row 9. Note to Row 13: This percentage is calculated based upon 114,824,231 shares of common stock of the Issuer outstanding as of January 8, 2026, as set forth in the Issuer's Form 424B5 filed with the Securities Exchange Commission on January 8, 2026.

SCHEDULE 13D

CUSIP No. 022307102

1

Name of reporting person

Foresite Labs, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,176,470.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 1,176,470.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

1,176,470.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.0 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Note to Row 7: 1,176,470 shares, all of which are directly owned by Labs Affiliates. Labs, the managing member of Labs Affiliates, may be deemed to have sole power to vote these shares, and Tananbaum, a manager of Labs, may be deemed to have shared power to vote these shares. Note to row 8: See response to row 7. Note to Row 9: 1,176,470 shares, all of which are directly owned by Labs Affiliates. Labs, the managing member of Labs Affiliates, may be deemed to have sole power to dispose of these shares, and Tananbaum, a manager of Labs, may be deemed to have shared power to dispose of these shares. Note to Row 10: See response to row 9. Note to Row 13: This percentage is calculated based upon 114,824,231 shares of common stock of the Issuer outstanding as of January 8, 2026, as set forth in the Issuer's Form 424B5 filed with the Securities Exchange Commission on January 8, 2026.

SCHEDULE 13D

CUSIP No. 022307102

1

Name of reporting person

James B. Tananbaum

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 15,013,334.00
8	Shared Voting Power 1,176,470.00
9	Sole Dispositive Power 15,013,334.00
10	Shared Dispositive Power 1,176,470.00

11

Aggregate amount beneficially owned by each reporting person

16,189,804.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

14.1 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Note to Row 7: 15,013,334 shares, of which 4,247,670 shares are directly owned by Fund VI, 5,702,536 shares are directly owned by Fund V, 194,459 shares are directly owned by Labs Co-Invest, 2,908,332 shares are directly owned by Opportunity Fund V, and 1,960,337 shares are directly owned by Labs Fund I. Tananbaum is the managing member of each of FCM VI, which is the general partner of Fund VI; FCM V, which is the general partner of Fund V and the managing member of Labs Co-Invest; FCOM V, which is the general partner of Opportunity Fund V; and FLM I, which is the general partner of Labs Fund I. Tananbaum may be deemed to have sole power to vote the shares directly owned by Fund VI, Fund V, Labs Co-Invest, Opportunity Fund V and Labs Fund I. Note to row 8: 1,176,470 shares, all of which are directly owned by Labs Affiliates. Labs, the managing member of Labs Affiliates, may be deemed to have sole power to vote these shares, and Tananbaum, a manager of Labs, may be deemed to have shared power to vote these shares. Note to Row 9: 15,013,334 shares, of which 4,247,670 shares are directly owned by Fund VI, 5,702,536 shares are directly owned by Fund V, 194,459 shares are directly owned by Labs Co-Invest, 2,908,332 shares are directly owned by Opportunity Fund V, and 1,960,337 shares are directly owned by Labs Fund I. Tananbaum is the managing member of each of FCM VI, which is the general partner of Fund VI; FCM V, which is the general partner of Fund V and the managing member of Labs Co-Invest; FCOM V, which is the general partner of Opportunity Fund V; and FLM I, which is the general partner of Labs Fund I. Tananbaum may be deemed to have sole power to dispose of the shares directly owned by Fund VI, Fund V, Labs Co-Invest, Opportunity Fund V and Labs Fund I. Note to Row 10: 1,176,470 shares, all of which are directly owned by Labs Affiliates. Labs, the managing member of Labs Affiliates, may be deemed to have sole power to dispose of these shares, and Tananbaum, a manager of Labs, may be deemed to have shared power to dispose of these shares. Note to Row 13: This percentage is calculated based upon 114,824,231 shares of common stock of the Issuer outstanding as of January 8, 2026, as set forth in the Issuer's Form 424B5 filed with the Securities Exchange Commission on January 8, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock
(b)	Name of Issuer: Alumis Inc.
(c)	Address of Issuer's Principal Executive Offices: 280 East Grand Avenue, South San Francisco, CALIFORNIA , 94080.
Item 1 Comment: This Amendment No. 3 ("Amendment No. 3") amends and restates the Statement on Schedule 13D initially filed on July 5, 2024 ("Original Schedule 13D"), as amended and restated by Amendment No. 1 filed with the Securities and Exchange Commission ("SEC") on May 7, 2025 and Amendment No. 2 filed with the Securities and Exchange Commission ("SEC") on June 10, 2025. This Amendment No. 3 relates to the beneficial ownership of Common Stock of Alumis, Inc., a corporation organized under the laws of the state of Delaware ("Issuer"). This Amendment No. 3 is being filed by Foresite Capital Fund VI, L.P. ("Fund VI"), Foresite Capital Management VI, LLC ("FCM VI"), Foresite Capital Fund V, L.P. ("Fund V"), Labs Co-Invest V, LLC ("Labs Co-Invest"), Foresite Capital Management V, LLC ("FCM V"), Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"), Foresite Capital Opportunity Management V, LLC ("FCOM V"), Foresite Labs Fund I, L.P. ("Labs Fund I"), Foresite Labs Management I, LLC ("FLM I"), Foresite Labs Affiliates 2021, LLC ("Labs Affiliates"), Foresite Labs, LLC ("Labs") and James B. Tananbaum ("Tananbaum" and together with Fund VI, FCM VI, Fund V, Labs Co-Invest, FCM V, Opportunity Fund V, FCOM V, Labs Fund I, FLM I, Labs Affiliates and Labs, the "Reporting Persons"). This Amendment No. 3 is being filed to (i) update the aggregate percentage of Common Stock owned by the Reporting Persons due to dilution caused by the Issuer's issuance of additional shares of its Common Stock from time to time since the date of the filing of the Amendment No. 2 that resulted in a decrease of over one percent (1%) in the aggregate percentage ownership reported by the Reporting Persons in the Amendment No. 2 and (ii) reflect the acquisition of Common Stock by Fund V and Opportunity Fund V.
Item 2.	Identity and Background
(a)	The persons and entities filing this Amendment No. 3 are Fund VI, FCM VI, Fund V, Labs Co-Invest, FCM V, Opportunity Fund V, FCOM V, Labs Fund I, FLM I, Labs Affiliates, Labs and Tananbaum. FCM VI, the general partner of Fund VI, may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer directly owned by Fund VI. FCM V, the general partner of Fund V and the managing member of Labs Co-Invest, may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer directly owned by Fund V and Labs Co-Invest. FCOM V, the general partner of Opportunity Fund V, may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer directly owned by Opportunity Fund V. FLM I, the general partner of Labs Fund I, may be deemed to have sole power to vote and sole power to dispose of the shares of the Issuer directly owned by Labs Fund I. Labs, the managing member of Labs Affiliates, may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer directly owned by Labs Affiliates. Tananbaum, the managing member of each of FCM VI, FCM V, FCOM V and FLM I may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer directly owned by Fund VI, Fund V, Labs Co-Invest, Opportunity Fund V and Labs Fund I. Tananbaum, a manager of Labs, may be deemed to have shared power to vote and sole power to dispose of shares of the Issuer directly owned by Labs Affiliates.
(b)	The address of the principal place of business for each of Fund VI, FCM VI, Fund V, Labs Co-Invest, FCM V, Opportunity Fund V, FCOM V, Labs Fund I, FLM I and Tananbaum is c/o Foresite Capital Management, LLC, 900 Larkspur Landing Circle, Suite 150, Larkspur, CA 94939. The address of the principal place of business for each of Labs Affiliates and Labs is c/o Foresite Labs, LLC, 101 Mission Street, 12th Floor, San Francisco, CA 94105.
(c)	The principal occupation of each of the Reporting Persons is the venture capital investment business. The principal business of each of Fund VI, Fund V, Labs Co-Invest, Opportunity Fund V, Labs Fund I and Labs Affiliates is to make investments in private and public companies. The principal business of FCM VI is to serve as the general partner of Fund VI, the principal business of FCM V is to serve as the general partner of Fund V and the managing member of Labs Co-Invest, the principal business of FCOM V is to serve as the general partner of Opportunity Fund V and the principal business of FLM I is to serve as the general partner of Labs Fund I. The principal business of Labs is to engage in the business of data science and incubation in the fields of life sciences and healthcare. Tananbaum is the managing member of each of FCM VI, FCM V, FCOM V and FLM I. Tananbaum is also a manager of Labs and a member of the board of directors of the Issuer.
(d)	During the last five years, none of the Reporting Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	Each of Fund VI, Fund V, Opportunity Fund V and Labs Fund I is a Delaware limited partnership. Each of FCM VI, FCM V, FCOM V, FLM I, Labs Co-Invest, Labs Affiliates and Labs is a Delaware limited liability company. Tananbaum is a U.S. citizen.
Item 3.	Source and Amount of Funds or Other Consideration
	Acquisition of Common Stock In February 2021, Labs Affiliates purchased an aggregate of 5,500,000 shares of Common Stock from the Issuer at a purchase price of $0.0001 per share, or $550 in the aggregate. Conversion of Simple Agreements for Future Equity (SAFEs) and Direct Purchase of Series Seed Redeemable Convertible Preferred Stock In February 2021, Fund V and Labs Co-Invest purchased an aggregate of 10,000,000 shares of Series Seed Redeemable Convertible Preferred Stock from the Issuer at a purchase price of $1.00 per share, or $10 million in the aggregate. The purchase price consisted of (i) $7,381,810.80 new cash investment by Fund V and the cancellation of $1,709,089.20 in SAFEs held by Fund V converted in connection with such financing, and (ii) $738,189.20 new cash investment by Labs Co-Invest and the cancellation of $170,910.80 in SAFEs held by Labs Co-Invest converted in connection with such financing. Direct Purchase of Series A Redeemable Convertible Preferred Stock In March 2021, Fund V purchased 5,250,000 shares of Series A Redeemable Convertible Preferred Stock and Opportunity Fund V purchased 2,250,000 shares of Series A Redeemable Convertible Preferred Stock at a purchase price of $4.00 per share, or $30.0 million in the aggregate. Convertible Promissory Notes In March 2021, the Issuer issued convertible promissory notes to Fund V, Opportunity V and Labs Fund I with a total principal amount of $30.0 million in exchange for $30.0 million in cash. In August 2021, the Issuer issued additional convertible promissory notes to Labs Fund I with a total principal amount of $1.5 million in exchange for $1.5 million in cash. In September 2021, the Issuer amended and restated all outstanding convertible promissory notes held by Fund V, Opportunity V and Labs Fund I and issued an additional convertible promissory note to Labs Fund I with a total principal amount of $6.0 million in exchange for $6.0 million in cash. Series B-1 Redeemable Convertible Preferred Stock Financing In December 2021, convertible notes held by Fund V, Opportunity V and Labs Fund I automatically converted into an aggregate 9,760,088 shares of Series B-1 Redeemable Convertible Preferred Stock of the Issuer at a conversion price of $4.00 per share, resulting in the cancellation of the Issuer's indebtedness of $39,040,356.18 in the aggregate. As a result, Fund V acquired 2,618,356 shares of Series B-1 Redeemable Convertible Preferred Stock of the Issuer, Opportunity Fund V acquired 2,618,356 shares of Series B-1 Redeemable Convertible Preferred Stock of the Issuer and Labs Fund I acquired 4,523,376 shares of Series B-1 Redeemable Convertible Preferred Stock of the Issuer. Direct Purchase of Series B-2 Redeemable Convertible Preferred Stock In May 2023, Fund V purchased an aggregate of 1,939,643 shares of Series B-2 Redeemable Convertible Preferred Stock of the Issuer, Opportunity Fund V purchased an aggregate of 969,821 shares of Series B-2 Redeemable Convertible Preferred Stock of the Issuer, Labs Fund I purchased an aggregate of 969,821 shares of Redeemable Convertible Preferred Stock of the Issuer, and Fund VI purchased an aggregate of 969,821 shares of Redeemable Convertible Preferred Stock of the Issuer at a price of $5.00 per share, or $24,245,530 in the aggregate. In October 2023, Fund V purchased an aggregate of 969,821 shares of Series B-2 Redeemable Convertible Preferred Stock of the Issuer, Opportunity Fund V purchased an aggregate of 484,910 shares of Series B-2 Redeemable Convertible Preferred Stock of the Issuer, Labs Fund I purchased an aggregate of 484,911 shares of Redeemable Convertible Preferred Stock of the Issuer, and Fund VI purchased an aggregate of 484,910 shares of Redeemable Convertible Preferred Stock of the Issuer at a price of $5.00 per share, or $12,122,760 in the aggregate. Direct Purchase of Series C Redeemable Convertible Preferred Stock In March 2024, Fund V purchased an aggregate of 2,389,859 shares of Series C Redeemable Convertible Preferred Stock of the Issuer, Opportunity Fund V purchased an aggregate of 1,593,239 shares of Series C Redeemable Convertible Preferred Stock of the Issuer, Labs Fund I purchased an aggregate of 1,593,239 shares of Series C Redeemable Convertible Preferred Stock of the Issuer, and Fund VI purchased an aggregate of 3,983,098 shares of Series C Redeemable Convertible Preferred Stock of the Issuer at a price of $3.13826 per share, or $29,999,992.48 in the aggregate. In May 2024, Fund V purchased an aggregate of 2,389,859 shares of Series C Redeemable Convertible Preferred Stock of the Issuer, Opportunity Fund V purchased an aggregate of 1,593,239 shares of Series C Redeemable Convertible Preferred Stock of the Issuer, Labs Fund I purchased an aggregate of 1,593,239 shares of Series C Redeemable Convertible Preferred Stock of the Issuer, and Fund VI purchased an aggregate of 3,983,098 shares of Series C Redeemable Convertible Preferred Stock of the Issuer at a price of $3.13826 per share, or $29,999,992.48 in the aggregate. Reverse Stock Split and Conversion On June 20, 2024, the Issuer effected a 1-for-4.675 reverse stock split of its issued and outstanding Common Stock, as a result of which Fund V held 1,944,577 shares of Series Seed Redeemable Convertible Preferred Stock of the Issuer; Labs Co-Invest held 194,459 shares of Series Seed Redeemable Convertible Preferred Stock of the Issuer; Fund V held 1,122,994 shares of Series A Redeemable Convertible Preferred Stock of the Issuer; Opportunity Fund V held 481,283 shares of Series A Redeemable Convertible Preferred Stock of the Issuer; Fund V held 560,076 shares of Series B-1 Redeemable Convertible Preferred Stock of the Issuer; Opportunity Fund V held 560,076 shares of Series B-1 Redeemable Convertible Preferred Stock of the Issuer; Labs Fund I held 967,567 shares of Series B-1 Redeemable Convertible Preferred Stock of the Issuer; Fund V held 622,344 shares of Series B-2 Redeemable Convertible Preferred Stock of the Issuer; Opportunity Fund V held 311,172 shares of Series B-2 Redeemable Convertible Preferred Stock of the Issuer; Labs Fund I held 311,172 shares of Series B-2 Redeemable Convertible Preferred Stock of the Issuer; Fund VI held 311,172 shares of Series B-2 Redeemable Convertible Preferred Stock of the Issuer; Fund V held 1,022,398 shares of Series C Redeemable Convertible Preferred Stock of the Issuer; Opportunity Fund V held 681,598 shares of Series C Redeemable Convertible Preferred Stock of the Issuer; Labs Fund I held 681,598 shares of Series C Redeemable Convertible Preferred Stock of the Issuer; Fund VI held 1,703,998 shares of Series C Redeemable Convertible Preferred Stock of the Issuer; and Labs Affiliates held 1,176,470 shares of Common Stock of the Issuer. In connection with the closing of the Issuer's initial public offering on July 1, 2024 (the "Initial Offering"), each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock, Series B-1 Redeemable Convertible Preferred Stock, Series B-2 Redeemable Convertible Preferred Stock and Series C Redeemable Convertible Preferred Stock automatically converted into one share of Common Stock. Purchase in Initial Offering In connection with the Initial Offering, Fund V purchased 312,500 shares of the Issuer's Common Stock from the underwriters for $16.00 per share, or $5,000,000.00 in the aggregate; and Fund VI purchased 2,187,500 shares of the Issuer's Common Stock from the underwriters for $16.00 per share, or $35,000,000.00 in the aggregate. Such purchases occurred pursuant to and on the terms set forth in the Issuer's Prospectus filed pursuant to Rule 424(b)(4) on June 28, 2024 with the Securities and Exchange Commission (File No. 333-280068) (the "Prospectus"). Open Market Purchase On May 2, 2025, Fund VI purchased 25,000 shares of the Issuer's Common Stock at a price of $4.62 per share, or $115,500 in the aggregate, in an open market purchase. On May 6, 2025, Fund VI purchased 20,000 shares of the Issuer's Common Stock at a price of $4.34 per share, or $86,800 in the aggregate, in an open market purchase. On November 17, 2025, Opportunity Fund V purchased (i) 50,000 shares of the Issuer's Common Stock at a price of $5.60 per share, or $280,000 in the aggregate, in an open market purchase and (ii) 150,000 shares of the Issuer's Common Stock at a price of $5.59 per share, or $838,500 in the aggregate, in an open market purchase On November 18, 2025, Opportunity Fund V purchased 117,374 shares of the Issuer's Common Stock at a price of $6.19 per share, or $726,545.06 in the aggregate, in an open market purchase. On November 19, 2025, Opportunity Fund V purchased 190,500 shares of the Issuer's Common Stock at a price of $6.56 per share, or $1,249,680 in the aggregate, in an open market purchase. On November 21, 2025, Opportunity Fund V purchased 72,212 shares of the Issuer's Common Stock at a price of $7.38 per share, or $532,924.56 in the aggregate, in an open market purchase. Follow-on Offering The Issuer filed a Prospectus Supplement pursuant to Rule 424(b)(5) on January 8, 2026 with the Securities and Exchange Commission (the "2026 Prospectus Supplement") that details the Issuer's offering of 17,650,000 shares of Common Stock (the "Follow-on Offering"). On January 8, 2026, in connection with the Follow-on Offering, Fund V purchased 117,647 shares of the Issuer's Common Stock at a price of $17.00 per share, or $1,999,999 in the aggregate and Opportunity Fund V purchased 294,117 shares of the Issuer's Common Stock at a price of $17.00 per share, or $4,999,989 in the aggregate. Such purchases occurred pursuant to and on the terms set forth in the 2026 Prospectus Supplement. Source of Funds The source of the funds for all purchases and acquisitions by Fund VI, Fund V, Labs Co-Invest, Opportunity Fund V, Labs Fund I and Labs Affiliates was from working capital. No part of the purchase price was borrowed by Fund VI, Fund V, Labs Co-Invest, Opportunity Fund V, Labs Fund I and Labs Affiliates for the purpose of acquiring any securities discussed in this Item 3.
Item 4.	Purpose of Transaction
	The Reporting Persons hold their securities of the Issuer for investment purposes. Depending on the factors discussed herein, the Reporting Persons may, from time to time, acquire additional shares of Common Stock and/or retain and/or sell all or a portion of the Common Stock held by the Reporting Persons in the open market or in privately negotiated transactions, and/or may distribute the Common Stock held by the Reporting Persons to their respective members or limited partners. Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons' review of numerous factors, including, among other things, the price levels of the Common Stock; general market and economic conditions; ongoing evaluation of the Issuer's business, financial condition, operations and prospects; the relative attractiveness of alternative business and investment opportunities; and other future developments. Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	Regarding aggregate beneficial ownership, see Row 11 of the cover page of each Reporting Person. Regarding percentage beneficial ownership, see Row 13 of the cover page of each Reporting Person. Regarding sole power to vote shares, see Row 7 of the cover page of each Reporting Person. Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person. Regarding sole power to dispose of shares, see Row 9 of the cover page of each Reporting Person. Regarding shared power to dispose of shares, see Row 10 of the cover page of each Reporting Person. The percentage listed in Row 13 for each Reporting Person was calculated based upon 95,819,723 shares of common stock of the Issuer outstanding as of May 21, 2025, as reported by the Issuer to the Reporting Persons.
(b)	See response to Item 5(a) above.
(c)	Except as set forth in Item 3 above, the Reporting Persons have not effected any transaction in the securities of the Issuer during the past 60 days.
(d)	Under certain circumstances set forth in the limited partnership agreement of each of Fund VI, Fund V, Opportunity Fund V and Labs Fund I and the limited liability company agreement of each of FCM VI, FCM V, FCOM V, FLM I, Labs Co-Invest, Labs Affiliates and Labs, the partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from the sale of, shares of the Issuer directly or indirectly owned by each such entity of which they are a partner or member.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	In connection with the issuance of the Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock, Series B-1 Redeemable Convertible Preferred Stock, Series B-2 Redeemable Convertible Preferred Stock and Series C Redeemable Convertible Preferred Stock of the Issuer, Fund VI, Fund V, Labs Co-Invest, Opportunity V, Labs Fund I and certain other investors entered into an Amended and Restated Investors' Rights Agreement dated March 4, 2024 (the "Rights Agreement"). The Rights Agreement grants to Fund VI, Fund V, Labs Co-Invest, Opportunity V, Labs Fund I and certain other parties thereto certain rights including demand registration rights, piggyback registration rights and Form S-3 registration rights. Such registration rights will expire, with respect to any particular stockholder, upon the earliest to occur of: (a) the closing of a Deemed Liquidation Event (as defined therein) (b) such time after consummation of the IPO (as defined therein) as Rule 144 or another similar exemption under the Securities Act (as defined therein) is available for the sale of all of such holder's shares without limitation during a three-month period without registration; or (c) the fifth anniversary of the IPO (as defined therein). The rights set forth in the Rights Agreement are more fully described in the Prospectus and incorporated herein by reference. Fund VI, Fund V, Labs Co-Invest, Opportunity V, Labs Fund I entered into a letter agreement with Morgan Stanley & Co, LLC, Leerink Partners LLC, Cantor Fitzgerald & Co., and Guggenheim Securities, LLC, as representatives of the underwriters, on March 4, 2024 (together, the "Lock-Up Agreements"). Pursuant to the Lock-Up Agreements, Fund VI, Fund V, Labs Co-Invest, Opportunity V, Labs Fund I and Tananbaum agreed that they would not, during the period ending 180 days after the date set forth on the Prospectus and subject to limited exceptions, (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock beneficially owned (as such term is used in Rule 13d-3 of the Securities Exchange Act of 1934, as amended), or any other securities so owned convertible into or exercisable or exchangeable for Common Stock or (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise. Such Lock-Up Agreement is more fully described in the Prospectus and incorporated herein by reference. In connection with the Follow-On Offering, each of Tananbaum, Fund V and Opportunity Fund V entered into a lock-up agreement, pursuant to which each such party agreed, subject to certain exceptions, not to sell, transfer or otherwise convey certain of the Issuer's securities held by Fund V or Opportunity Fund V for 60 days following the date of the 2026 Prospectus Supplement. The terms and provisions of such lock-up agreement are described more fully in 2026 Prospectus Supplement, and the above summary is qualified by reference to such description and the full text of the lock-up agreement, a form of which is filed as Exhibit E to this Statement and is incorporated herein by reference. Tananbaum, in his capacity as a director of the Issuer, along with the other directors of the Issuer, entered into an Indemnification Agreement with the Issuer. Such Indemnification Agreement is more fully described in the Prospectus and incorporated herein by reference.
Item 7.	Material to be Filed as Exhibits.
	EXHIBIT A Agreement of Joint Filing. The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Alumis, Inc. shall be filed on behalf of each of the Reporting Persons. Note that copies of the applicable Agreement of Joint Filing are already on file with the appropriate agencies. EXHIBIT B Amended and Restated Investors' Rights Agreement, filed on June 7, 2024 as Exhibit 4.2 to the Issuer's Registration Statement on Form S-1 (File No. 333-80068), and incorporated herein by reference. EXHIBIT C Form of Lock-Up Agreement, filed as Exhibit A to the Underwriting Agreement filed on June 24, 2024 as Exhibit 1.1 to the Issuer's Amendment No. 2 to Form S-1 Registration Statement (File No. 333-80068), and incorporated herein by reference. EXHIBIT D Form of Indemnification Agreement, filed as Exhibit 10.10 to the Issuer's Amendment No. 2 to Form S-1 Registration Statement (File No. 333-80068) is incorporated herein by reference. EXHIBIT E Form of Lock-Up Agreement, filed as Exhibit A to the Underwriting Agreement filed on January 9, 2026 as Exhibit 1.1 to the Issuer's Form 8-K (File No. 001-42143), and incorporated herein by reference.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Foresite Capital Fund VI LP

Signature:	/s/ James B. Tananbaum
Name/Title:	James Tananbaum, Managing Member of the General Partner
Date:	01/12/2026

Foresite Capital Management VI, LLC

Signature:	/s/ James B. Tananbaum
Name/Title:	James Tananbaum, Managing Member
Date:	01/12/2026

Foresite Capital Fund V, L.P.

Signature:	/s/ James B. Tananbaum
Name/Title:	James Tananbaum, Managing Member of the General Partner
Date:	01/12/2026

Labs Co-Invest V, LLC

Signature:	/s/ James B. Tananbaum
Name/Title:	James Tananbaum, Managing Member of the General Partner
Date:	01/12/2026

Foresite Capital Management V, LLC

Signature:	/s/ James B. Tananbaum
Name/Title:	James Tananbaum, Managing Member
Date:	01/12/2026

Foresite Capital Opportunity Fund V, L.P.

Signature:	/s/ James B. Tananbaum
Name/Title:	James Tananbaum, Managing Member of the General Partner
Date:	01/12/2026

Foresite Capital Opportunity Management V, LLC

Signature:	/s/ James B. Tananbaum
Name/Title:	James Tananbaum, Managing Member
Date:	01/12/2026

Foresite Labs Fund I, L.P.

Signature:	/s/ James B. Tananbaum
Name/Title:	James Tananbaum, Managing Member of the General Partner
Date:	01/12/2026

Foresite Labs Management I, LLC

Signature:	/s/ James B. Tananbaum
Name/Title:	James Tananbaum, Managing Member
Date:	01/12/2026

Foresite Labs Affiliates 2021, LLC

Signature:	/s/ James B. Tananbaum
Name/Title:	James Tananbaum, Managing Member of the Manager
Date:	01/12/2026

Foresite Labs, LLC

Signature:	/s/ James B. Tananbaum
Name/Title:	James Tananbaum, Manager
Date:	01/12/2026

James B. Tananbaum

Signature:	/s/ James B. Tananbaum
Name/Title:	James B. Tananbaum
Date:	01/12/2026

FAQ

How much of Alumis (ALMS) stock does James B. Tananbaum report owning?

James B. Tananbaum reports beneficial ownership of 16,189,804 shares of Alumis common stock, representing 14.1% of the outstanding shares, through various Foresite funds and affiliated entities.

Which Foresite funds are reporting Alumis (ALMS) ownership in this Schedule 13D/A?

The filing covers Foresite Capital Fund VI, L.P., Foresite Capital Fund V, L.P., Labs Co-Invest V, LLC, Foresite Capital Opportunity Fund V, L.P., Foresite Labs Fund I, L.P., Foresite Labs Affiliates 2021, LLC, and their related management LLCs, together with James B. Tananbaum.

What triggered this Amendment No. 3 to the Alumis (ALMS) Schedule 13D?

The amendment is being filed to update the aggregate ownership percentage after dilution from Alumis issuing additional common stock and to reflect new acquisitions of common stock by Fund V and Opportunity Fund V.

At what prices did the Foresite funds buy Alumis (ALMS) shares in the IPO and follow-on offering?

In the initial public offering, Fund V bought 312,500 shares and Fund VI bought 2,187,500 shares at $16.00 per share. In the January 8, 2026 follow-on offering, Fund V bought 117,647 shares and Opportunity Fund V bought 294,117 shares at $17.00 per share.

What open-market purchases of Alumis (ALMS) stock are disclosed by Foresite funds?

Disclosed open-market buys include Fund VI purchases of 25,000 shares at $4.62 per share and 20,000 shares at $4.34 per share in May 2025, and Opportunity Fund V purchases in November 2025 such as 50,000 shares at $5.60, 150,000 shares at $5.59, 117,374 shares at $6.19, 190,500 shares at $6.56, and 72,212 shares at $7.38 per share.

What is the stated purpose of Foresite’s investment in Alumis (ALMS)?

The reporting persons state they hold Alumis securities for investment purposes. They may acquire additional shares, retain, sell, or distribute shares based on factors such as Alumis’s business and financial condition, the stock price, general market conditions, and alternative opportunities.

Are there any notable agreements affecting Foresite’s Alumis (ALMS) shares?

Yes. The filing references an Amended and Restated Investors' Rights Agreement granting registration rights, and lock-up agreements tied to the IPO and the January 2026 follow-on offering, under which certain Foresite entities and James B. Tananbaum agreed to restrictions on selling or transferring Alumis securities for specified periods.